Skip to main content

This job has expired

You will need to login before you can apply for a job.

Engineer II, mRNA Process Development and Manufacturing

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Mar 21, 2023

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

In this Engineer II role, you will be responsible for building tools required for the development of novel mRNA synthetic and purification processes in support of our lead in vivo gene editing therapeutic candidates as well as future programs. To this end, you will leverage your biochemical engineering / biochemistry experiences to fully develop efficient processes required for Nucleic Acids manufacturing. You will help advance our gene editing candidates such as NTLA2001 into a commercial process. You will also explore the broad spectrum of process development tools to develop and scale up next-generation nucleic acid therapeutics in support of Intellia’ s gene-editing platform technologies.

About You:

As an ideal candidate for this role, you have worked in process development and/or manufacturing science teams to advance biotherapeutic drug substances or cell therapeutics into late-stage clinical studies. Additionally, you have experience working with nucleic acids (e.g. mRNA or DNA) and understand basic biochemistry principles and analytical techniques necessary to characterize the product and impurities. In this role, you will work with the process development team to

  • Design and perform process characterization studies for key unit operations e.g., enzymatic reactions, tangential flow filtration (TFF, UF/DF). Analyze experimental data and draw sound scientific conclusions.

  • Use DoE principles to optimize in vitrotranscription process that is robust and scalable.

  • Contribute to development of next-generation mRNA design and synthesis.

  • Provide high quality Electronic Lab Notebook (ELN) documentations. Author and review technical reports.

  • Lead and/or assist in manufacturing science activities, including manufacturing technical investigations, scale-up, and tech transfer to a CDMO, managing change controls, etc.

  • Contribute to process validation activities e.g., authoring validation study protocols and executing lab experiments.

  • Assist in maintaining general laboratory functionality and supplies.

Required Skills:

  • Proven record of successfully planning and executing lab experiments and projects.

  • Lab experience in process development or manufacturing support/ manufacturing science setting.

  • Strong communication skills. Able to clearly express ideas and point of view both verbally and in writing.

  • Experience in scale-up and/or tech transfer to internal or external GMP manufacturing facilities.

  • Ability to multitask within a dynamic team environment and ability to work with ambiguity.

Preferred Skills:

  • Experience with process validation and/or process characterization using Design of Experiments (DoE) methodologies.

  • Experience with enzymatic reactions such as in vitro transcription.

  • Hands-on experience in analysis of DNA/RNA or proteins.

Your training will include a Bachelor’s degree in Chemical Engineering, Biochemical Engineering, Biochemistry, or related area with 5+ years, or a master’s degree with 2+ years of hands-on industrial experience. The level can be commensurate with the candidate’s experience. Most importantly, if you have an enthusiastic curiosity to develop mRNA processes and learn about the future of medicine in gene editing, we strongly encourage you to apply!

Meet your future team:

The Nucleic Acid Process Sciences team is a fun and energetic team of scientists and engineers focused on the internal development of nucleic acid therapeutics to create the curative gene editing technologies of the future. As a team, we drive the late-stage development of Intellia’s mRNA drug substance(s) for Intellia’s lead programs. Furthermore, we are responsible for the development of enzymatic process and characterization tools to build a wide range of nucleic acid modalities for Intellia’s next generation platform technologies. We have an interesting and diverse background and set of experiences reflecting the breadth and depth of our responsibilities, and we look forward to meeting and welcoming onboard the next member of the team!

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert